V110

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Pneumococcal InfectionPneumococcal disease

Phase 3

Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)

CompletedNCT05158140

Merck Sharp & Dohme LLCPneumococcal Infection

Start: 2022-01-12End: 2023-02-21Updated: 2025-07-18

A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety, Tolerability, and Immunogenicity of V116 in Children and Adolescents With Increased Risk of Pneumococcal Disease.

CompletedCTIS2023-506236-32-00

Merck Sharp & Dohme LLCPneumococcal disease

Start: 2024-03-25End: 2025-02-25Target: 215Updated: 2025-02-25

Related Papers

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age

Vaccines2025-02-153 citations